Amgen says Nplate addresses medical needs
8 June 2009 00:00 in Pharmaceutical Company Product News
Amgen's Nplate (romiplostim) addresses an unmet medical need for patients, the firm has stated.
The company discussed data of a study comparing the medication to the standard care in non-splenectomised adult patients with chronic immune thrombocytopenic purpura.
A low platelet count in the blood is a main characteristic of the condition, which can lead to serious bleeding events.
Patients who took Nplate gained a number of benefits in the study - including reduced bleeding, explained head haematology at the Hospital of the Justus-Liebig University in Germany Dr Mathias Rummel.
"Nplate is a unique treatment option that can help us better manage patients with chronic ITP ?. It increases platelet production and avoids immune suppression," he commented.
The findings from the study were presented at the 14th congress of European Haematology Association yesterday (June 7th).
Last month, Amgen announced results of a survey that revealed a large number of oncologists and infectious disease specialists are worried about the damage an infection could cause to patients undergoing chemotherapy.
Other news stories from 08/06/2009
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency